Quantifying neurobehavioral profiles across neurodevelopmental genetic syndromes and idiopathic neurodevelopmental disorders
Genetic syndromes associated with neurodevelopmental disorders present with unique neurobehavioral profiles that can inform selection of outcome measures in future clinical trials. The NET may be a useful screening and monitoring instrument in clinical practice, where frequent in-person clinic attendance is difficult for many patients.
Authors
- Constance L. Smith‐Hicks (ORCID: https://orcid.org/0000-0001-8241-9574)
- Patricia Klaas
- Robyn M. Busch (ORCID: https://orcid.org/0000-0002-5442-4912)
- Antonio Y. Hardan (ORCID: https://orcid.org/0000-0002-9860-8625)
- Thomas William Frazier (ORCID: https://orcid.org/0000-0002-6951-2667)
- Mirko Uljarević (ORCID: https://orcid.org/0000-0002-7481-3923)
- Katherine Lachlan (ORCID: https://orcid.org/0000-0002-3816-7346)
- Mustafa Şahin (ORCID: https://orcid.org/0000-0001-7044-2953)
- Eva Loth (ORCID: https://orcid.org/0000-0001-9458-9167)
Institutions
- Boston Children's Hospital (US)
- Kennedy Krieger Institute (US)
- Harvard University (US)
- Johns Hopkins University (US)
- John Carroll University (US)
- King's College London (GB)
- SUNY Upstate Medical University (US)
- University Hospital Southampton NHS Foundation Trust (GB)
- Cleveland Clinic Lerner College of Medicine (US)
- Center for Pain and the Brain (US)
- Stanford University (US)
Publication Details
- Journal
- Developmental Medicine & Child Neurology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1111/dmcn.16112
- Citations
- 4
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 1.37
Funders
- Autism Speaks
- Simons Foundation
- Bristol-Myers Squibb
- Roche
- Biogen
- F. Hoffmann-La Roche
- GW Pharmaceuticals
- PTEN Research
- Quadrant Biosciences
- Astellas Pharma
- Oryzon Genomics
- National Institutes of Health